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cense. httpAbstract Purpose: Increasing interest in the Quality of Life outcomes in cancer patients led to
increase implementation of their use in routine clinical practice. The aim of this systemic review
is to review the scientiﬁc evidence behind recommending the use of quality of life (QoL) scales rou-
tinely in outpatient evaluation.
Methods: Systematic review for all published randomized controlled trials in English language
between January 1, 1990 till December 31, 2012. Out of 487 articles (476 identiﬁed by electronic
search + 11 articles identiﬁed bymanual search), six trials satisﬁed the eligibility criteria: (1) the study
was a randomized controlled trial (RCT) with randomization of patients or health care providers; (2)
the ﬁndings of the administered questionnaire or scale (the intervention) were given to health care pro-
vider, and compared to standard care with no questionnaire administered (the control); (3) study was
conducted in outpatient oncology clinics; and (4) an outcome was measured that related to (i) QoL
improvement, (ii) reduction in morbidity, (iii) reduction in stress for the patients, (iv) improvement
in communication between patients and health care provider, or (v) improved patient satisfaction.
Assessment for the quality of the study was done using the GRADE methodology.
Results: Serious methodological issues were affecting most of the trials. Overall the evaluation of the
quality of the evidence from these identiﬁed trials suggests that there is a weak recommendation to use
QoL scales in routine oncology practice to improve communication between physicians and patients.
Conclusion: The routine use of such tools in the outpatient settings at improving the patient outcome
or satisfaction cannot be recommended based on the available evidence. The potential harm with thee National Cancer Institute,
g by Elsevier
ng by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
://dx.doi.org/10.1016/j.jnci.2013.03.001
64 K. Alsalehexcess use of resources needed to implement, collect, store, analyse, and present such data to health
care providers should be also considered. Further research and better designed trials is required using
recent methodological techniques such as item-response theory based questionnaire and cluster ran-
domization might help to reach an answer to this question.
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Interest in Quality of Life (QoL) measurement has been
increasing in cancer research. This is evident by the number
of scales being developed, and increasing incorporation of
QoL measurement as the primary endpoint in randomized
controlled trails of therapeutic interventions [1]. Publications
in the cancer-related QoL ﬁeld have tripled in the past decade
compared to the preceding 25 years [2].
There are reasons which might explain the increasing inter-
est in QoL in cancer research. Chemotherapy and radiation
therapy are associated with signiﬁcant toxicities which affect
QoL [3] and, in many cases, palliation of symptoms and
improvement in QoL are the primary goals of treatment rather
than prolongation of life [4]. Many cancer-related therapeutic
interventions are costly with minimal improvement in overall
survival and, therefore, need to be justiﬁed based on cost-effec-
tiveness [5] which often requires measurement of QoL and util-
ities (e.g. quality adjusted life year). Improvement in treatment
of cancers in the pediatric and young adult population has re-
sulted in greatly improved survivorship; monitoring of func-
tional and emotional disability [6], which are key aspects of
QoL, is important in the care of these patients.
The important and valuable results obtained from the clin-
ical trials that included QoL evaluation has led to a logic in-
crease interest in using QoL scales in routine clinical
practice. Many major academic cancer centers do this includ-
ing Memorial Sloan-Kettering Cancer Center, Johns Hopkins,
and the M.D. Anderson Cancer Center [7]. A decision aid has
been made available on-line and for use with personal hand-
held devices to facilitate the use of standardized symptom scale
for patient management by Cancer Care Ontario (CCO) [8].The goals behind collecting QoL data in routine practice in-
clude: identifying and managing symptoms, monitoring dis-
ease progression and improving communication between
patients and health care providers [9]. Although all of these
goals are valuable, it is uncertain if they are achieved by rou-
tine collection of QoL data at each clinic visit.
The goals of this paper is: (1) to review the evidence that the
use of such scales inﬂuences patient management for random-
ized controlled trials (RCTS); (2) to evaluate the evidence that
the use of such scales resulted in better patient care (i.e. im-
proved outcomes) and; (3) to review the methodology of these
trials and suggesting future directions in research.Literature review
To address the ﬁrst goal of this paper, a literature review was
performed with the aim of identifying all randomized con-
trolled trials that have evaluated the routine use of QoL mea-
surement in oncology clinics. A supplementary literature
search, using a less restrictive strategy, was performed to re-
trieved articles, reviews, and book chapters that addressed
the other three goals of this paper.
Data sources
Using the electronic Ovid search engine; Medline, Embase and
Psychinfo were searched using the following search keywords
(‘‘patient reported outcome’’ or ‘‘health status’’ or ‘‘functional
status’’ or ‘‘quality of life’’ or ‘‘QoL’’) and (‘‘cancer’’ or
‘‘oncology’’ or ‘‘neoplasm’’). All keywords were expanded to
include related terms using the ‘explode’ function whenever
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sults. The search results were further screened by examining
the title or abstract for the following terms: ‘‘clinical practice’’,
‘‘consultation’’, ‘‘longitudinal data’’, ‘‘individual’’, ‘‘intra-indi-
vidual’’, ‘‘intraindividual’’, ‘‘diary’’, ‘‘daily’’ or ‘‘recurrent’’.
The titles and abstracts of the retrieved articles were then re-
viewed to see if they addressed any of the three goals, in which
case the full text was reviewed.
The search terms were partially selected based on previous
systematic reviews [10,11] and by using key words that were
used in landmark articles in this ﬁeld.
It has been noted, computerized literature searching of this
type of topic is more difﬁcult and less reliable than searches
that focus on traditional medical interventions [12]. Therefore,
I supplemented the search by manual search of relevant data-
base and expert advice. The search was restricted to adults and
articles published in English.
Selection of studies
RCTs were included in this review if: (1) the study was a ran-
domized controlled trial (RCT) with randomization of patients
or health care providers; (2) the ﬁndings of the administered
questionnaire or scale (the intervention) were given to health
care provider, and compared to standard care with no ques-
tionnaire administered (the control) or to administration of a
questionnaire with the ﬁndings not given to health care provid-
ers (‘‘attention control’’); (3) study was conducted in outpa-
tient oncology clinics; and (4) an outcome was measured that
related to (i) QoL improvement, (ii) reduction in morbidity,
(iii) reduction in stress for the patients, (iv) improvement in
communication between patients and health care provider,
or (v) improved patient satisfaction.
This review excluded studies conducted exclusively in pure
palliative care settings or inpatients, as this was not the focus
of this review. It also excluded studies with fewer than 50 pa-
tients because of the high risk of publication bias associated
with very small studies [13]. The search included publications
between January 1, 1990 till December 31, 2012.
Results
Six studies were identiﬁed [14–19] that fulﬁlled the eligibility
criteria, and summarized in (Table 1). The ﬂow for studies
selection is shown in Fig. 1. Five of these studies used the
European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire, (EORTC QLQ-C30). The stud-
ies will be discussed with overall assessment of the ﬁndings
according to the selected outcomes of this review either posi-
tive, negative or equivocal.
Analysis of the six studies
Trowbridge [14] randomized oncologists to receive the ﬁndings
of completed questionnaires or not to receive the ﬁndings; all
the patients completed the questionnaires. A total of 510 con-
secutive patients with metastatic or recurrent cancer completed
a questionnaire about self-rated pain at baseline and then
4 weeks later. Changes in Cleeland’s pain management index
[20] and analgesics use were measured. Using Mcnemar’s test
there was an improvement in the pain rating (p= 0.05) andan increase in analgesic use (p= 0.016). The study showed
that the using of the QoL scale helped in improving patient
care (Positive study).
Taenzer [15] randomized 57 patients with lung cancer to
complete the EORTC QLQ-C30 before clinic visits with the re-
sults provided to the physicians vs. Control arm to completion
of the questionnaire after the visits with result not provided to
their physicians. Both groups completed The Patient Satisfac-
tion Questionnaire (PDIS) [21] and underwent chart audits.
Differences in the scores of the EORTC QLQ-C30 and PDIS
were reported and the charts were reviewed to identify the dif-
ferent categories of QoL discussed with patients. There was a
better score of physical functioning (p< 0.05) and less dysp-
nea (p< 0.05) on the control arm. There was no difference
in patients’ satisfaction between the two groups (Negative
study).
McLachlan [16] study, randomized 450 patients to complete
the EORTC QLQ-C30, the Beck Depression Inventory (BDI)
short form and the Cancer Need Questionnaire (CNQ), with
the result provided to the treating physician plus an individu-
alized psychiatric intervention for patients at risk of depression
vs. standard management where the questionnaires were
administered but the result were not provided to their physi-
cians. The result showed that there was no difference in the
CNQ assessment for psychological need or information needs
at 2 months (the primary endpoint). There was also no differ-
ence between the 2 groups on the BDI or EORTC QLQ-C30 at
2 or 6 months (a secondary outcome). There was no impact on
the consultation time (Negative study).
Detmar [17] randomized, in cross-over trial, 10 physicians
with a total of 214 patients with advanced cancer on chemo-
therapy. Initially, Researchers randomized half of the physi-
cians to receive result of the completed EORTC QLQ-C30
scale while the other half continued with the conventional
way without administration of the questionnaire. After a
washout period of 2 months, physicians crossed over to the
other arm. There was a better score on checklist for patient-
physician communication as assessed by blinded rater for
tape-recorded clinic visits. There was a better physician’s
awareness of patient’s QoL issues as assessed by agreement be-
tween physicians and patients rating of symptoms on the Dart-
mouth Primary Care Cooperative Information Functional
Health Assessment (COOP) and the World Organisation Pro-
ject of National Colleges and Academics (WONCA) charts
[22]. There was no effect on length of visit time (Postive result).
Velikova [18], randomized 286 patients who were receiving
chemotherapy to one of three groups: completion of the
EORTC QLQ-C30 and Hospital Anxiety and Depression
Scale (HADS) with feedback to the physicians; completion
of the questionnaires with no feedback to physicians (atten-
tion-control); and a pure control group with no questionnaire
completed. The primary outcomes were (i) patients QoL mea-
sured using the Functional Assessment of Cancer Therapy-
General questionnaire (FACT-G); and (ii) physician–patient
communication as measured by blinded content analysis of
tape-recorded encounters. Patient QoL sores were better in
the intervention and attention-control groups with overall bet-
ter QoL compared to pure control group (p= 0.01), especially
for emotional well-being. There was no difference between the
intervention and attention-control groups and no difference in
patient management between the three groups. There was also
no effect on clinic visit time (Negative study).
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Figure 1 The ﬂow for studies identiﬁcation, inclusion and exclusion.
Routine administration of standardized questionnaires that assess aspects 67Mills [19] randomized patients with inoperable lung cancer
were randomized to complete a weekly EORTC QLQ-C30 and
lung cancer module (LC13) [23] for 16 weeks with result pro-
vided to the physicians vs. no completion of a questionnaire.
The outcome was assessed by the Functional Assessment of
Cancer Therapy–Lung (FACT-L) scale and patient satisfac-
tion on six-question questionnaire. At four months there was
worse QoL score in the intervention arm (p= 0.05) with no
difference in satisfaction (Negative study).
In summary the studies had different methods to address
the question about the beneﬁts of the QoL data in clinical
practice. Despite EORTC QLQ-C30 being used in 5 of the tri-
als, other scales have been utilized with no clear explanation
for their selection. There was diversity of outcome measures
which used qualitative measures; including satisfaction, com-
munication or improving care.
Methodological assessment of reviewed trials
There are many methodological issues with the above men-
tioned trials, including that the randomization process was
not described in three studies [14,16,19] or that valid random-
ization did not occur in a fourth study [15]; as the patients were
enrolled in sequence to the control and intervention arms.
Lack of valid random allocation has the potential to introduce
bias due to systematic differences in prognostic factors at base-
line. In addition, even if there had been valid randomization, it
is uncertain if measures were taken to assure allocation con-
cealment (i.e. that investigator could not manipulate patient
assignment to different groups) [24]. Such manipulations are
also likely to result in systematic imbalances in prognostic fac-
tors that are known to inﬂuence outcomes. Sample size calcu-
lations [25] were not provided in 2 studies [14,15], which
undermines conﬁdence in the power of the studies to detect
or exclude clinically important differences.Four of the studies [14–16,19] did not report all the details,
as indicated by the CONSORT guidelines for reporting RCTs,
which further hampers interpretation of these ﬁndings (i.e.
were all randomized patients included in the analysis; were
there losses to follow [see below]) [26].
Due to the nature of these interventions, patients and
healthcare providers cannot be blinded. This can result in a
number of problems including biased outcome assessment, dif-
ferential use of co-interventions, and contamination of the
control arm with the intervention. To overcome the problem
of biased outcome assessment, two studies had assessment of
clinic visit audio tapes by assessors who were blinded to the pa-
tient allocation [17,18].
Contamination of the control arm could occur if use of the
questionnaire in the intervention arm lead to physicians paying
closer attention to assessment of QoL issues in the control
arm. Intention-to-treat analysis [27] was conducted in two tri-
als [17,18]. This was difﬁcult to ascertain on the other four tri-
als since ‘‘as treated’’ group analysis was provided.
All of the studies; except one [15] had more than 20% of
subjects lost to follow up. It was usually not clear if the loss
to follow-up was due to death from the cancer, or if it was
due to other causes.
Overall evaluation of the studies
Based on the six studies; the evidence for or against routine use
of questionnaires (or other QoL instruments) in medical oncol-
ogy clinics is of low quality [28]. Using the GRADE approach
to assessing quality, the main limitations are the potential for
bias (lack of blinding, possible lack of concealment, large and
poorly explained losses to follow-up) and imprecision (wide
conﬁdence intervals on estimates and uncertainty around
power calculations). However, even with the potential for bias
that would be expected to favour the intervention, only two
68 K. Alsalehout of the six studies [14,17,29,30] suggested any beneﬁt from
routine administration of QoL questionnaires. In addition, this
practice is expected to be associated with considerable resource
utilization and cost (not formally assessed in any of the stud-
ies) and it might be even harmful (causes stress for patients).
The ﬁndings of the six studies in a formal meta-analysis
could not be done because of major heterogeneity between
studies in terms of clinical differences between patients, study
design and the outcomes that were assessed.
Discussion
There are many issues related to strengths and limitations of
using QoL instruments in routine practice in oncology. These
issues can be classiﬁed [31] as related to the (1) scale, (2) clini-
cian, (3) patient and (4) the health care system.
Scale issues
Important scale issues include: (1) suitability for use in a
wide range of clinical settings; (2) ease of use; and (3) scale
responsiveness.
It is unclear what is the most suitable scale to be used, most
of the literature support the use of EORTC QLQ-30C but this
not consistent with across physicians and patients [32].
Most currently used QoL scales were developed using clas-
sical test theory (CTT) and generalizability theory [33] which
might not be optimized to solve the above issues. These tech-
niques have serious limitations as those methods were opti-
mized to average the responses for different patients and
were used commonly to compare groups rather than differ-
ences among individuals. This will limit the ability of the scale
to detect change for the individual score unless it is large dif-
ference [34]. To use one scale in different clinical scenarios it
would need to assess a wide variety of domains (i.e. to be mul-
ti-faceted/multi-dimensional questionnaire). It is also impor-
tant to keep QoL questionnaires brief for ease of completion
[35].
Item response theory (IRT) might represent a solution for
some the above mentioned limitations of QoL scales [36]. This
allows for the development of computerized adaptive testing
which is gauged for each individual and allow for better com-
parisons between patients. IRT-driven questionnaires in oncol-
ogy require extensive testing with large populations (item
banking) and special expertise, and only a few such studies
have appeared in the literature [37].
Clinician issues
The value of administering QoL scales in routine clinical prac-
tice has been questioned by clinicians who feel that they are
better able to obtain the same information by talking to the
patients in a less structured way during clinic visits [16,37].
Presentation and analysis of routinely collected QoL data is
another issue that needs to be considered [38]. Should physi-
cians pay attention to the current score or to the trend, and
what constitutes an important difference? In four of the above
reviewed trials [14–16,19] no formal training was given to the
health care providers to guide them on how to interpret the
QoL data, which further limits the utility of this data. One
way to help with the interpretability of QoL data on anindividual level is to establish minimal important difference
[40]. This is achieved by two methods: distribution based, or
the anchoring method [38,41].
Patient related issues
The acceptability of such intervention needs to be established
by determining if patients believe that they are of value to them
or are an excessive burden. Acceptability is inﬂuenced by mul-
tiple issues such as the length of the scale, availability of trans-
lated validated versions, and belief that the scale addresses
issues that patient’s value.
Patient anxiety is another potential disadvantage of rou-
tinely administering QoL questionnaires. In recent studies, pa-
tients with terminal cancer have been shown to have an
increased level of anxiety [39], and possibly lengthening of con-
sultation time [41], when they are provided with a prompt list
compared to receiving standard care. Despite the prompt list
being different than the QoL questionnaires, they do share
many domains. However, as noted above, consultation time
was not affected by administration of the QoL questionnaires
in three randomized controlled trials.
Health care system issues
In order to integrate QoL questionnaires into routine clinical
practice, it is important to have the resources to capture, reg-
ister and review the QoL data [42]. It is important to have both
pen and paper versions and computer versions available for
the ease of use and archiving the scores with ease of accessibil-
ity. However, elderly patients may have difﬁculty with inter-
pretation of questions, or recording of answers [44]. Few
programs like Cancer Care Ontario captures symptoms ques-
tionnaire data (ESAS) and assumes that completeness of this
process is indicative of quality but, until it is proven that cap-
turing this data improves outcomes for the patients; this
assumption may not be justiﬁed.
Conclusion
Evidence for the use of symptom questionnaires or QoL scales
in daily clinical practice is limited. There is some evidence sug-
gesting that this might improve communication between pa-
tients and health caregivers but, because this evidence is of
low quality, this is also uncertain. Currently, there is no good
evidence that routine administration of QoL questionnaires
improve patient’s QoL or changes management. In addition,
QoL questionnaires is associated with costs, may be stressful
for patients. Consequently, the overall impression is that rou-
tine administration of questionnaires in medical oncology out-
patient clinics is currently hardly justiﬁed.
Before further implementing such an intervention on a large
scale, RCTs need to conﬁrm its beneﬁts. One potential design
to conﬁrm the usefulness of in routine practice might require a
cluster randomization [43].
Disclosures
I, Dr. Khalid Al-Saleh, indicate that for the article entitled
‘‘Routine administration of standardized questionnaires that
assess aspects of patients’ quality of life in medical oncology
Routine administration of standardized questionnaires that assess aspects 69clinics: A Systematic review’’, have no relevant ﬁnancial rela-
tionship or conﬂict of interest. This research received no exter-
nal funding. I have full control of all primary data and agree to
allow the journal to review the data if requested.
References
[1] Joly F, Vardy J, Pintilie M, Tannock IF. Quality of life and/or
symptom control in randomized clinical trials for patients with
advanced cancer. Ann Oncol 2007;18(12):1935–42.
[2] Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes
in cancer: a review of recent research and policy initiatives. CA
Cancer J Clin 2007;57(5):278–300.
[3] Skeel R, Khleif S. Handbook of cancer chemother-
apy. Lippincott Williams &Wilkins; 2011.
[4] Grunfeld EA, Maher EJ, Browne S, Ward P, Young T, Vivat B,
et al. Advanced breast cancer patients’ perceptions of decision
making for palliative chemotherapy. J Clin Oncol 2006;24(7):
1090–8.
[5] Fojo T, Grady C. How much is life worth: cetuximab, non-small
cell lung cancer, and the $440 billion question. J Natl Cancer
Inst 2009;101(15):1044–8.
[6] Moe PJ, Holen A, Glomstein A, Madsen B, Hellebostad M,
Stokland T, et al. Long-term survival and quality of life in
patients treated with a national all protocol 15–20 years earlier:
IDM/HDM and late effects? Pediatr Hematol Oncol 1997;14(6):
513–24.
[7] Basch E, Abernethy AP. Commentary: encouraging clinicians to
incorporate longitudinal patient-reported symptoms in routine
clinical practice. J Oncol Pract/Am Soc Clin Oncol 2011;
7(1):23–5.
[8] SymptomManagement Tools – CCO<https://www.cancercare.
on.ca/cms/One.aspx?portalId=1377&pageId=58189>.
[9] Luckett T, Butow PN, King MT. Improving patient outcomes
through the routine use of patient-reported data in cancer
clinics: future directions. Psychooncology 2009;18(11):1129–38.
[10] Espallargues M, Valderas JM, Alonso J. Provision of feedback
on perceived health status to health care professionals: a
systematic review of its impact. Med Care 2000;38(2):175–86.
[11] Valderas JM, Kotzeva A, Espallargues M, Guyatt G, Ferrans
CE, Halyard MY, et al. The impact of measuring patient-
reported outcomes in clinical practice: a systematic review of the
literature. Qual Life Res 2008;17(2):179–93.
[12] O’Leary N, Tiernan E, Walsh D, Lucey N, Kirkova J, Davis M.
The pitfalls of a systematic MEDLINE review in palliative
medicine: symptom assessment instruments. Am J Hosp Palliat
Care 2007;24(3):181.
[13] Ioannidis JP, Cappelleri JC, Lau J. Issues in comparisons
between meta-analyses and large trials. JAMA 1998;279(14):
1089–93.
[14] Trowbridge R, Dugan W, Jay SJ, Littrell D, Casebeer LL,
Edgerton S, Anderson J, O’Toole JB. Determining the
effectiveness of a clinical-practice intervention in improving
the control of pain in outpatients with cancer. Acad Med 1997;
72(9):798–800.
[15] Taenzer P, Bultz BD, Carlson LE, Speca M, DeGagne T, Olson
K, Doll R, Rosberger Z. Impact of computerized quality of life
screening on physician behaviour and patient satisfaction in lung
cancer outpatients. Psychooncology 2000;9(3):203–13.
[16] McLachlan SA, Allenby A, Matthews J, Wirth A, Kissane D,
Bishop M, Beresford J, Zalcberg J. Randomized trial of
coordinated psychosocial interventions based on patient self-
assessments versus standard care to improve the psychosocial
functioning of patients with cancer. J Clin Oncol 2001;19(21):
4117–25.
[17] Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson
NK. Health-related quality-of-life assessments and patient–physician communication: a randomized controlled trial.
JAMA 2002;288(23):3027–34.
[18] Velikova G, Booth L, Smith AB, Brown PM, Lynch P,
Brown JM, Selby PJ. Measuring quality of life in routine
oncology practice improves communication and patient well-
being: a randomized controlled trial. J Clin Oncol
2004;22(4):714–24.
[19] Mills ME, Murray LJ, Johnston BT, Cardwell C, Donnelly M.
Does a patient-held quality-of-life diary beneﬁt patients with
inoperable lung cancer? J Clin Oncol 2009;27(1):70–7.
[20] Cleeland CS, Gonin R, Hatﬁeld AK, Edmonson JH, Blum RH,
Stewart JA, Pandya KJ. Pain and its treatment in outpatients
with metastatic cancer. N Engl J Med 1994;330(9):592–6.
[21] Falvo DR, Smith JK. Assessing residents’ behavioral science
skills: patients’ views of physician–patient interaction. J Fam
Pract 1983;17(3):479–83.
[22] Nelson E, Wasson J, Kirk J, Keller A, Clark D, Dietrich A,
et al. Assessment of function in routine clinical practice:
description of the COOP chart method and preliminary
ﬁndings. J Chronic Dis 1987;40(Suppl. 1S):55S–69, PMID:
3597698 [PubMed - indexed for MEDLINE].
[23] Nicklasson M, Bergman B. Validity, reliability and clinical
relevance of EORTC QLQ-C30 and LC13 in patients with chest
malignancies in a palliative setting. Qual Life Res
2007;16(6):1019–28.
[24] Schulz KF, Grimes DA. Allocation concealment in randomised
trials: defending against deciphering. Lancet 2002;359(9306):
614–8.
[25] Schulz KF, Grimes DA. Sample size slippages in randomised
trials: exclusions and the lost and wayward. Lancet
2002;359(9308):781–5.
[26] Hopewell S, Clarke M, Moher D, Wager E, Middleton P,
Altman DG, et al. CONSORT Group: CONSORT for
reporting randomized controlled trials in journal and
conference abstracts: explanation and elaboration. PLoS Med
2008;5(1):e20.
[27] Fergusson D, Aaron SD, Guyatt G, He´bert P. Post-
randomisation exclusions: the intention to treat principle and
excluding patients from analysis. BMJ 2002;325(7365):652–4.
[28] Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,
Alonso-Coello P, et al. GRADE Working Group: GRADE: an
emerging consensus on rating quality of evidence and strength of
recommendations. BMJ 2008;336(7650):924–6.
[29] Donaldson M. Taking stock of health-related quality-of-life
measurement in oncology practice in the United States. J Natl
Cancer Inst Monogr 2004:155–67.
[30] Snyder CF, Dy SM, Hendricks DE, Brahmer JR, Carducci MA,
et al. Asking the right questions: investigating needs
assessments and health-related quality-of-life questionnaires
for use in oncology clinical practice. Support Care Cancer
2007;15(9):1075–85.
[31] Streiner D, Norman G. Health measurement scales: a practical
guide to their development and use. USA: Oxford University
Press; 2008.
[32] Frost MH, Bonomi AE, Ferrans CE, Wong GY, Hays RD.
Clinical Signiﬁcance Consensus Meeting Group: patient,
clinician, and population perspectives on determining the
clinical signiﬁcance of quality-of-life scores. Mayo Clin Proc
2002;77(5):488–94.
[33] Cella D, Gershon R, Lai JS, Choi S. The future of outcomes
measurement: item banking, tailored short-forms, and
computerized adaptive assessment. Qual Life Res 2007;
16(Suppl. 1):133–41.
[34] Ganz PA, Gotay CC. Use of patient-reported outcomes in phase
III cancer treatment trials: lessons learned and future directions.
J Clin Oncol 2007;25(32):5063–9.
[35] Kaasa S, Loge JH. Quality of life in palliative care: principles
and practice. Palliat Med 2003;17(1):11–20.
70 K. Alsaleh[36] Stro¨mgren AS, Groenvold M, Pedersen L, Olsen AK, Spile M,
Sjøgren P. Does the medical record cover the symptoms
experienced by cancer patients receiving palliative care? A
comparison of the record and patient self-rating. J Pain
Symptom Manage 2001;21(3):189–96.
[37] Velikova G, Wright P, Smith AB, Stark D, Perren T, Brown J,
Selby P. Self-reported quality of life of individual cancer
patients: concordance of results with disease course and
medical records. J Clin Oncol 2001;19(7):2064–73.
[38] Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR.
Clinical Signiﬁcance Consensus Meeting Group: methods to
explain the clinical signiﬁcance of health status measures. Mayo
Clin Proc 2002;77(4):371–83.
[39] Brown RF, Butow PN, Dunn SM, Tattersall MH. Promoting
patient participation and shortening cancer consultations: a
randomised trial. Br J Cancer 2001;85(9):1273–9.
[40] Bedard G, Zeng L, Lam H, Cella D, Zhang L, Lauzon N, et al.
Meaningful change in oncology quality-of-life instruments: asystematic literature review. Expert Rev Pharmacoecon
Outcomes Res 2012;12(4):475–83.
[41] Clayton JM, Butow PN, Tattersall MHN, Devine RJ, Simpson
JM, Aggarwal G, et al. Randomized controlled trial of a
prompt list to help advanced cancer patients and their caregivers
to ask questions about prognosis and end-of-life care. J Clin
Oncol 2007;25(6):715–23.
[42] Rose M, Bezjak A. Logistics of collecting patient-reported
outcomes (PROs) in clinical practice: an overview and practical
examples. Qual Life Res 2009;18(1):125–36.
[43] Fayers PM. Evaluating the effectiveness of using PROs in
clinical practice: a role for cluster-randomised trials. Qual Life
Res 2008;17(10):1315–21.
[44] Bainbridge D, Seow H, Sussman J, Pond G, Martelli-Reid L,
Herbert C, et al. Multidisciplinary health care professionals’
perceptions of the use and utility of a symptom assessment
system for oncology patients. J Oncol Pract/Am Soc Clin Oncol
2011;7(1):19–23.
